Alzheon captures former IVAX president

6 August 2018

Alzheon, a privately-held American biopharmaceutical company, has announced its hiring of former IVAX president Neil Flanzraich as vice chairman of the board.

Mr Flanzraich, an early investor in the company who had previously served a three-month stint as chief business officer in early 2018, will lead the board of directors alongside former GlaxoSmithKline (LSE: GSK) chief executive Jean-Pierre Garnier.

"We are delighted to have Neil serve as the vice chairman of our board of directors and to contribute his expertise to Alzheon in this new role," said Martin Tolar, president and chief executive of Alzheon. "Neil has an exceptional track record for driving business strategies and building value in biopharmaceutical companies. We look forward to his insights and guidance, as we chart our future course for the clinical development of ALZ-801 in Alzheimer’s disease, and continue our strategy to bring breakthrough therapies to patients with neurodegenerative disorders."

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK